Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Verastem Inc (NASDAQ:VSTM)

7.27
Delayed Data
As of 3:59pm ET
 -0.36 / -4.72%
Today’s Change
6.78
Today|||52-Week Range
12.35
-20.46%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$278.8M

Company Description

Verastem, Inc. is a clinical biopharmaceutical company, which is focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells. The company is developing small molecule inhibitors of signaling pathways which includes Focal Adhesion Kinase FAK, PI3K/mTOR and Wnt that are critical to cancer stem cell survival and proliferation. Verastem was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg and Christoph H. Westphal on August 4, 2010 and is headquartered in Cambridge, MA.

Contact Information

Verastem, Inc.
117 Kendrick Street
Needham Massachusetts 02494
P:(781) 292-4200
Investor Relations:
(617) 252-9314

Employees

Shareholders

Other institutional30.68%
Individual stakeholders29.23%
Mutual fund holders24.11%

Top Executives

Robert M. ForresterPresident, Chief Executive Officer & Director
Daniel W. PatersonChief Operating Officer
John B. GreenChief Financial Officer & Chief Accounting Officer
Jonathan PachterVice President & Head-Research
Brian SullivanHead-Corporate Development & Investor Relations